Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

被引：29
|
作者：
Ying, Tianlei [1 ]
Li, Haoyang [1 ]
Lu, Lu [1 ]
Dimitrov, Dimiter S. [2 ]
Jiang, Shibo [1 ,3 ]
机构：
[1] Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol MOE MOH, Shanghai 200032, Peoples R China
[2] NCI, Prot Interact Sect, Canc & Inflammat Program, Ctr Canc Res,NIH, Frederick, MD 21702 USA
[3] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA
来源：
MICROBES AND INFECTION | 2015年 / 17卷 / 02期
基金：
中国国家自然科学基金;
关键词：
Coronavirus; MERS-CoV; mAbs; Receptor binding domain (RBD); RESPIRATORY SYNDROME CORONAVIRUS; RECEPTOR-BINDING DOMAIN; POTENT NEUTRALIZATION; SARS CORONAVIRUS; BAT CORONAVIRUS; SPIKE PROTEIN; SAUDI-ARABIA; VIRUS; IDENTIFICATION; THERAPEUTICS;
D O I：
10.1016/j.micinf.2014.11.008
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak poses a serious threat to public health. Here, we summarize recent advances in identifying human neutralizing monoclonal antibodies (mAbs) against MERS-CoV, describe their mechanisms of action, and analyze their potential for treatment of MERS-CoV infections. (C) 2014 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：142 / 148
页数：7
相关论文
共 50 条
  • [21] MERS-CoV as an emerging respiratory illness: A review of prevention methods
    Baharoon, Salim
    Memish, Ziad A.
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2019, 32
  • [22] Development of Small-Molecule MERS-CoV Inhibitors
    Liang, Ruiying
    Wang, Lili
    Zhang, Naru
    Deng, Xiaoqian
    Su, Meng
    Su, Yudan
    Hu, Lanfang
    He, Chen
    Ying, Tianlei
    Jiang, Shibo
    Yu, Fei
    VIRUSES-BASEL, 2018, 10 (12):
  • [23] MERS-CoV spillover at the camel-human interface
    Dudas, Gytis
    Carvalho, Luiz Max
    Rambaut, Andrew
    Bedford, Trevor
    ELIFE, 2018, 7
  • [24] MERS-CoV: Understanding the Latest Human Coronavirus Threat
    Chafekar, Aasiyah
    Fielding, Burtram C.
    VIRUSES-BASEL, 2018, 10 (02):
  • [25] MERS-CoV vaccine candidates in development: The current landscape
    Modjarrad, Kayvon
    VACCINE, 2016, 34 (26) : 2982 - 2987
  • [26] Dromedary MERS-CoV replicates in human respiratory tissues
    Reperant, Leslie A.
    Osterhaus, Albert D. M. E.
    LANCET RESPIRATORY MEDICINE, 2014, 2 (10): : 779 - 781
  • [27] Use of the Human Coronavirus 2012 (MERS) GeneSig kit for MERS-CoV detection
    Hoteit, Rouba
    Shammaa, Dina
    Mahfouz, Rami
    GENE REPORTS, 2016, 4 : 67 - 69
  • [28] Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2)
    Navand, Azadeh Haghi
    Soltani, Saber
    Moghadami, Mona
    Hosseini, Parastoo
    Nasimzadeh, Sepideh
    Zandi, Milad
    JOURNAL OF ACUTE DISEASE, 2020, 9 (06) : 244 - 247
  • [29] Comparison of incubation period distribution of human infections with MERS-CoV in South Korea and Saudi Arabia
    Victor Virlogeux
    Vicky J. Fang
    Minah Park
    Joseph T. Wu
    Benjamin J. Cowling
    Scientific Reports, 6
  • [30] Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection
    Raj, V. Stalin
    Okba, Nisreen M. A.
    Gutierrez-Alvarez, Javier
    Drabek, Dubravka
    van Dieren, Brenda
    Widagdo, W.
    Lamers, Mart M.
    Widjaja, Ivy
    Fernandez-Delgado, Raul
    Sola, Isabel
    Bensaid, Albert
    Koopmans, Marion P.
    Segales, Joaquim
    Osterhaus, Albert D. M. E.
    Bosch, Berend Jan
    Enjuanes, Luis
    Haagmans, Bart L.
    SCIENCE ADVANCES, 2018, 4 (08):
12345